SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Pazoo Inc (OTCMKTS:PZOO) a 40% stake owner in MA and Associates, LLC announced the formation of the MA Marketing and Sales segment. The new segment will be headed up by recently hired sales representative Michael A. Tulimero. He is an experienced and highly regarded sales executive in the Cannabis market, formerly heading up sales for firm Steep Hill in the Southern California region. Additionally, his prior experience at Steep Hill extended to representing the company at the renowned High Times Cannabis Cup conferences conducted in Los Angeles and Amsterdam.

The measures

Since Nevada has not announced the proper percentages of pesticides that are utilized for growth, the first pot product is not anticipated to be delivered for assessment until late June, 2015. Despite this delay, MA and Associates is moving forward with creation of the best customer and sales team in Nevada. Pazoo’s appointment of Tulimero highlights MA’s commitment to recruiting a sales team with extensive knowledge and experience in the Cannabis industry. The recruitment of specialized sales staff along with the oral and contractual commitments to evaluate product from a large number of growers provides MA a sales leadership position increasing its market share when the first product is launched for testing.

The other details

Bringing of the expert sales leadership by Pazoo Inc (OTCMKTS:PZOO) supports MA’s commitment to excellence. The company has a distinct competitive edge as it received by far the highest Nevada rating of any testing laboratory aspirant. With the delay in State regulatory guidance and product delivery, MA will postpone their soft opening of 4/20. The objective is to focus on a planned full launch which avoids extra cost and time for a ceremonial opening.

In last trading session, the stock price of Pazoo declined 12.63% to close the trading session at $0.00865 on share volume of 32.83 million compared to average volume of 23.44 million.